Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
11/23/2020 11/24/2020 11/25/2020 11/26/2020 11/27/2020 Date
84.09(c) 84.21(c) 84.22(c) 85.37(c) 85.21(c) Last
1 796 901 2 422 873 2 515 815 1 441 766 2 252 811 Volume
-2.05% +0.14% +0.01% +1.37% -0.19% Change
More quotes
Financials
Sales 2020 36 357 M 43 494 M 43 494 M
Net income 2020 11 732 M 14 035 M 14 035 M
Net Debt 2020 7 972 M 9 537 M 9 537 M
P/E ratio 2020 9,15x
Yield 2020 3,75%
Sales 2021 37 829 M 45 255 M 45 255 M
Net income 2021 5 851 M 7 000 M 7 000 M
Net Debt 2021 5 763 M 6 895 M 6 895 M
P/E ratio 2021 17,9x
Yield 2021 3,93%
Capitalization 107 B 128 B 128 B
EV / Sales 2020 3,16x
EV / Sales 2021 2,98x
Nbr of Employees 100 409
Free-Float 89,0%
More Financials
Company
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (84.1%): for the treatment of cardio-vascular diseases, thrombosis, central nervous system disorders (insomnia, multiple sclerosis, epilepsy), cancers, allergies, etc. Moreover, Sanofi-Aventis markets OTC products and generic drugs; - human vaccines (15.9%): pediatric vaccines,... 
Sector
Pharmaceuticals
Calendar
02/05Earnings Release
More about the company
Notations Surperformance© of Sanofi
Trading Rating : Investor Rating :
More Ratings
All news about SANOFI
11:40aTen COVID-19 vaccines seen by mid-year, head of global pharma group says
RE
11/26French health minister confirms vaccination could start by end of year
RE
11/25How will Canada's COVID-19 vaccine program work?
RE
11/25SANOFI : EC approves new meningitis vaccine
AQ
11/25EXPLAINER : When and how will COVID-19 vaccines become available?
RE
11/24SANOFI : - European Commission approves MenQuadfi, the latest innovation in meni..
AQ
11/24EU secures 160 million doses of Moderna's COVID-19 vaccine
RE
11/23SANOFI : Disclosure of trading in own shares
AQ
11/23SANOFI : Disclosure of trading in own shares
GL
11/23SANOFI : European Commission approves MenQuadfi®, the latest innovation in menin..
PU
11/23SANOFI : European Commission approves MenQuadfi®, the latest innovation in menin..
AQ
11/23SANOFI : European Commission approves MenQuadfi®, the latest innovation in menin..
GL
11/23SANOFI : European Commission approves MenQuadfi®, the latest innovation in menin..
AQ
11/19SANOFI : - European Commission approves Supemtek for the prevention of influenza..
AQ
11/19SANOFI : - FDA grants priority review for avalglucosidase alfa, a potential new ..
AQ
More news
News in other languages on SANOFI
02:46pRappel d'un lot d'un antiépileptique en raison d'un risque de surdosage
04:40aVERBAND WARNT VOR EUPHORIE :  Herstellung von Corona-Impfstoff knifflig
11/25La rémunération des dirigeants du CAC 40 en baisse de 10% en 2019 (rapport)
11/24Coronavirus-Macron ne veut pas de vaccination obligatoire
11/24EU schließt Impfstoff-Vertrag mit Moderna ab
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 11/19
A trend reversal can be anticipated
BUY
More Stock Trading Analysis
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 103,49 €
Last Close Price 85,21 €
Spread / Highest target 38,5%
Spread / Average Target 21,5%
Spread / Lowest Target -0,25%
EPS Revisions
Managers
NameTitle
Paul Hudson Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-4.92%127 702
JOHNSON & JOHNSON-1.50%378 244
ROCHE HOLDING AG-3.47%285 939
NOVARTIS AG-11.58%203 854
PFIZER INC.-1.59%203 048
MERCK & CO., INC.-11.97%202 555